<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03634982</url>
  </required_header>
  <id_info>
    <org_study_id>RMC-4630-01</org_study_id>
    <nct_id>NCT03634982</nct_id>
  </id_info>
  <brief_title>Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors</brief_title>
  <official_title>A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants With Relapsed/Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Revolution Medicines, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Revolution Medicines, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and
      pharmacodynamic (PD) profiles of escalating doses of RMC-4630 monotherapy in adult
      participants with relapsed/refractory solid tumors and to identify the recommended Phase 2
      dose (RP2D).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multicenter, Phase 1 study of oral RMC-4630 monotherapy in
      participants with advanced relapsed or refractory solid tumors. The study will include 2
      components: 1) a Dose-Escalation Component for participants with relapsed or refractory solid
      tumors and 2) a Dose-Expansion Component for participants with relapsed or refractory solid
      tumors harboring certain specific mutations/rearrangements that result in hyperactivation of
      the RAS-MAPK pathway. Participants will be treated until disease progression per RECIST v1.1,
      unacceptable toxicity, or other criteria for withdrawal are met, whichever occurs first.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Incidence, nature, and severity of treatment-emergent AEs and serious AEs, including incidence and severity of findings in laboratory values and vital signs for RMC-4630 monotherapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities (DLTs)</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence and nature of DLTs with RMC-4630 monotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Peak plasma concentration of RMC-4630</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Time to achieve peak plasma concentration of RMC-4630</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Area under the plasma concentration time curve of RMC-4630</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Elimination half-life of RMC-4630</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Ratio of accumulation of RMC-4630 from a single dose to steady state with repeated dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pERK</measure>
    <time_frame>up to 3 years</time_frame>
    <description>On-treatment versus baseline comparison of pharmacodynamic markers of RMC-4630 (e.g., pERK [phosphorylated form of extracellular signal-regulated kinase]) on peripheral blood mononuclear cells or newly obtained tumor samples by immunoassays or immunohistochemistry (IHC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Overall response rate of RMC-4630 per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Duration of response of RMC-4630 per RECIST v1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>RMC-4630</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RMC-4630 for oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RMC-4630</intervention_name>
    <description>RMC-4630 for oral administration</description>
    <arm_group_label>RMC-4630</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant (male or female) â‰¥18 years of age

          -  Participants who have advanced solid tumors that have failed, are intolerant to, or
             are considered ineligible for standard of care anticancer treatments including
             approved drugs for oncogenic drivers in their tumor type

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

          -  Participants in the Dose-Expansion Component must have one of the following genotypic
             aberrations: RTK mutations, amplifications or rearrangements, KRASG12, BRAF Class 3,
             or NF1 LOF mutations

          -  Adequate hematologic, hepatic and renal function

          -  Participant able to understand and voluntarily sign the informed consent form (ICF)
             and able to comply with the study visit schedule and other protocol requirements.

          -  Participants willing to agree to not father a child/become pregnant and comply with
             effective contraception criteria

        Exclusion Criteria:

          -  Known or suspected leptomeningeal or brain metastases or spinal cord compression

          -  Primary central nervous system (CNS) tumors

          -  Clinically significant cardiac disease

          -  Active, clinically significant interstitial lung disease or pneumonitis

          -  History or current evidence of retinal pigment epithelial detachment (RPED), central
             serous retinopathy, retinal vein occlusion (RVO), or predisposing factors to RPED or
             RVO

          -  Known HIV infection

          -  Active/chronic hepatitis B or C infection

          -  Any other unstable or clinically significant concurrent medical condition that would,
             in the opinion of the investigator, jeopardize the safety of a participant, impact
             their expected survival through the end of the study participation, and/or impact
             their ability to comply with the protocol prior/concomitant therapy

          -  Females who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Revolution Medicines, Inc.</last_name>
    <role>Study Director</role>
    <affiliation>Revolution Medicines, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Revolution Medicines, Inc.</last_name>
    <phone>(650) 779-2300</phone>
    <email>CT-Inquiries@RevMed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Honor Health Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Schaffer</last_name>
      <phone>480-323-1791</phone>
      <email>joschaffer@honorhealth.com</email>
    </contact>
    <investigator>
      <last_name>Michael Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianna Koczywas, MD</last_name>
      <phone>626-256-4673</phone>
      <phone_ext>83793</phone_ext>
      <email>MKoczywas@coh.org</email>
    </contact>
    <investigator>
      <last_name>Marianna Koczywas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Irvine - Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sai-Hong Ignatius Ou, MD, PhD</last_name>
      <phone>877-824-3627</phone>
      <email>ucstudy@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Sai-Hong Ignatius Ou, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steffany Lim, CCRP</last_name>
      <phone>916-734-0561</phone>
      <email>sllim@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Riess, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Francisco - Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Nalbandian</last_name>
      <phone>415-514-4681</phone>
      <email>Gregory.Nalbandian@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Caroline McCoach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Wells</last_name>
      <phone>720-848-0755</phone>
      <email>TARA.WELLS@CUANSCHUTZ.EDU</email>
    </contact>
    <investigator>
      <last_name>Jose Pacheco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute - Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terri Peterson</last_name>
      <phone>941-377-9993</phone>
      <email>tpeterson@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Judy Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffit Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Germaine M GonzÃ¡lez-Vazquez</last_name>
      <phone>813-745-6636</phone>
      <email>germaine.gonzalezvazquez@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Eric Haura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryan Marion</last_name>
      <phone>617-632-3383</phone>
      <email>bryan_marion@dfci.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kaitlin Morton</last_name>
      <phone>617-582-8013</phone>
      <email>kaitlin_morton@dfci.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Pasi Janne, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma - Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dena Suthers</last_name>
      <phone>405-271-8778</phone>
      <phone_ext>option 2</phone_ext>
      <email>SCC-Clinical-Trials-Office@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Susanna Ulahannan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute - Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dee McComb</last_name>
      <phone>615-329-7478</phone>
      <email>researchreferrals@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Howard Burris, III, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas at Austin - Dell Medical School</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Capasso</last_name>
      <phone>512-495-5516</phone>
      <email>anna.capasso@austin.utexas.edu</email>
    </contact>
    <investigator>
      <last_name>Gail Eckhardt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 10, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SHP2</keyword>
  <keyword>PTPN11</keyword>
  <keyword>NSCLC</keyword>
  <keyword>EGFR</keyword>
  <keyword>RTK</keyword>
  <keyword>KRAS G12</keyword>
  <keyword>BRAF Class 3</keyword>
  <keyword>NF1 LOF</keyword>
  <keyword>advanced solid tumor</keyword>
  <keyword>advanced solid malignancies</keyword>
  <keyword>melanoma</keyword>
  <keyword>skin cancer</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>endometrium/uterus cancer</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>cervical cancer</keyword>
  <keyword>Carcinoma, Non-Small-Cell Lung</keyword>
  <keyword>Neoplasms, Squamous Cell</keyword>
  <keyword>Carcinoma, Squamous Cell</keyword>
  <keyword>Esophageal Neoplasms</keyword>
  <keyword>Carcinoma, Bronchogenic</keyword>
  <keyword>Bronchial Neoplasms</keyword>
  <keyword>Lung Neoplasms</keyword>
  <keyword>Respiratory Tract Neoplasms</keyword>
  <keyword>Thoracic Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Neoplasms, Glandular and Epithelial</keyword>
  <keyword>Gastrointestinal Neoplasms</keyword>
  <keyword>Digestive System Neoplasms</keyword>
  <keyword>Head and Neck Neoplasms</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Esophageal Diseases</keyword>
  <keyword>Gastrointestinal Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

